scispace - formally typeset
S

Steven A. Leibel

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  146
Citations -  17846

Steven A. Leibel is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Radiation therapy & Prostate cancer. The author has an hindex of 72, co-authored 146 publications receiving 17450 citations. Previous affiliations of Steven A. Leibel include Radiation Therapy Oncology Group & Stanford University.

Papers
More filters
Journal ArticleDOI

Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality.

TL;DR: The concept of integrating physical and biological conformality in multidimensional conformal radiotherapy (MD-CRT) is explored and the concept of "biological target volume" (BTV) is proposed and hypothesized that BTV can be derived from biological images and that their use may incrementally improve target delineation and dose delivery.
Journal ArticleDOI

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

TL;DR: The data provide evidence for a significant effect of dose escalation on the response of human prostate cancer to irradiation and defines new standards for curative radiotherapy in this disease.
Journal ArticleDOI

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients

TL;DR: These data demonstrate the feasibility of high-dose IMRT in a large number of patients and demonstrate that short-term PSA control rates seem to be at least comparable to those achieved with three-dimensional conformal radiotherapy at similar dose levels.
Journal ArticleDOI

High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer

TL;DR: Sophisticated conformal radiotherapy techniques with high dose 3-D conformal and intensity modulated radiation therapy improve the biochemical outcome in patients with favorable, intermediate and unfavorable risk prostate cancer.